Navigation Links
Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Date:11/9/2009

e analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involv
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
2. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
3. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
4. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
5. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
6. Pharmasset Reports Fiscal Year End 2008 Financial Results
7. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... 28 de agosto de 2015   Royal ... participación en el  Congreso de la ESC de ... recientes y novedosas, entre ellas HeartModel A.I.  , ... personas y la tecnología con los protocolos de ... los tratamientos y permitir atención en el hogar. ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
(Date:8/28/2015)... ... 28, 2015 , ... SharkNinja, an innovative leader in the ... actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the ... a variety of sizes and styles while achieving the perfect brew richness level ...
(Date:8/28/2015)... ... 28, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Founded in 1924 and headquartered in Pittsburgh, Pennsylvania, ... their goals. Within the past 10 years, TJS Insurance Group has emerged as ...
(Date:8/28/2015)... Knoxville, TN (PRWEB) , ... August 28, 2015 , ... ... surrounding the Centers for Medicare & Medicaid Services’ (CMS) proposal to mandate bundled ... 45-minute webinar , “Get Ready for Game Day: Comprehensive Care for Joint Replacement,” ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Santa Rosa ... to Work in Healthcare by Modern Healthcare. In the KLAS “2015 Midterm Performance Review: ... , “We believe the recognitions from Modern Healthcare and KLAS are directly related ...
(Date:8/27/2015)... Caicos Islands, BWI (PRWEB) , ... August 28, 2015 , ... ... for weddings. This award is added to an already impressive list of accolades ... Grace Bay was ranked as the #2 beach in the world by TripAdvisor, the ...
Breaking Medicine News(10 mins):Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Grace Bay Beach Acknowledged as a Top Caribbean Beach for Weddings 2
... in the recent years. But a new study has found ... took such vows. // ,The study also questions ... gauging how well they adhere to these pledges, reports foodconsumer.org. ... or written declarations to remain a virgin until marriage. ...
... in the arm for researchers of biological intelligence in the ... resemble a baby infant’s learning process, aided by it’s ... roboticists from Italy, France and Switzerland, is an ingenious effort ... similar manner of experimenting with objects available, and imbibing the ...
... the US it was found that the condition has fast ... disorder that is afflicting an estimated 300,000 U.S. schoolchildren, or ... estimate contraindicates with the estimate of 1 in every 2,000 ... about an argument as to whether the higher prevalence reflects ...
... as a beneficial and healthy activity. With the emphasis slowly, ... there’s nothing like a bit of gardening to rev up ... Institute at Northwestern Memorial Hospital in Chicago says that the ... when you bend down at your knees. "It's going to ...
... Syndrome or the shaking leg syndrome is a common type of ... their legs//. For the first time Europe has approved the drug ... and causes aches and pains. Statistics show that about 10% of ... was given by the European Medicines Agency. As of now it ...
... non-hormonal male contraceptive device that targets sperms, called Intra Vas ... study// involving 90 men. Men and women have long been ... this first male contraceptive to be marketed market may not ... place in Seattle, Washington and St. Paul, Minnesota, will bring ...
Cached Medicine News:Health News:Teenagers Often Deny Taken ‘Virginity Pledges 2Health News:Burn Away Calories In Your Garden 2Health News:Non-Hormonal Male Contraceptive Based on Sperm Block Underway 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: